Yasuaki Muramatsu

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Journal: Breast cancer (Tokyo, Japan)

Published: January 27, 2026

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.

Journal: Breast cancer (Tokyo, Japan)

Published: August 18, 2025

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis.

Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis.

Journal: Breast cancer (Tokyo, Japan)

Published: March 05, 2025

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).

Journal: Breast cancer (Tokyo, Japan)

Published: January 28, 2025

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.

Journal: Future oncology (London, England)

Published: December 21, 2024

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Journal: Breast cancer (Tokyo, Japan)

Published: December 03, 2024

Epidemiology of adverse events related to sports among community people: a scoping review.

Epidemiology of adverse events related to sports among community people: a scoping review.

Journal: BMJ open

Published: June 12, 2024

Association between physical activity and quality of life in Japanese adults aged 85 to 89 years: a cross-sectional study.

Association between physical activity and quality of life in Japanese adults aged 85 to 89 years: a cross-sectional study.

Journal: BMC geriatrics

Published: September 15, 2023

Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.

Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.

Journal: Breast cancer (Tokyo, Japan)

Published: August 02, 2023

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan.

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan.

Journal: Breast (Edinburgh, Scotland)

Published: February 27, 2023

Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.

Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.

Journal: Future oncology (London, England)

Published: March 21, 2022

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.

Journal: Breast cancer (Tokyo, Japan)

Published: June 23, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026